Acute GVHD prophylaxis plus ATLG after myeloablative allogeneic haemopoietic peripheral blood stem-cell transplantation from HLA-identical siblings in patients with acute myeloid leukaemia in remission : final results of quality of life and long-term outcome analysis of a phase 3 randomised study

Show full item record



Permalink

http://hdl.handle.net/10138/311714

Citation

Bonifazi , F , Solano , C , Wolschke , C , Sessa , M , Patriarca , F , Zallio , F , Nagler , A , Selleri , C , Risitano , A M , Messina , G , Bethge , W , Herrera , P , Sureda , A , Carella , A M , Cimminiello , M , Guidi , S , Finke , J , Sorasio , R , Ferra , C , Sierra , J , Russo , D , Benedetti , E , Milone , G , Benedetti , F , Heinzelmann , M , Pastore , D , Jurado , M , Terruzzi , E , Narni , F , Voelp , A , Ayuk , F , Ruutu , T & Kroeger , N 2019 , ' Acute GVHD prophylaxis plus ATLG after myeloablative allogeneic haemopoietic peripheral blood stem-cell transplantation from HLA-identical siblings in patients with acute myeloid leukaemia in remission : final results of quality of life and long-term outcome analysis of a phase 3 randomised study ' , The lancet. Haematology , vol. 6 , no. 2 , pp. E89-E99 . https://doi.org/10.1016/S2352-3026(18)30214-X

Title: Acute GVHD prophylaxis plus ATLG after myeloablative allogeneic haemopoietic peripheral blood stem-cell transplantation from HLA-identical siblings in patients with acute myeloid leukaemia in remission : final results of quality of life and long-term outcome analysis of a phase 3 randomised study
Author: Bonifazi, Francesca; Solano, Carlos; Wolschke, Christine; Sessa, Mariarosaria; Patriarca, Francesca; Zallio, Francesco; Nagler, Arnon; Selleri, Carmine; Risitano, Antonio Maria; Messina, Giuseppe; Bethge, Wolfgang; Herrera, Pilar; Sureda, Anna; Carella, Angelo Michele; Cimminiello, Michele; Guidi, Stefano; Finke, Juergen; Sorasio, Roberto; Ferra, Christelle; Sierra, Jorge; Russo, Domenico; Benedetti, Edoardo; Milone, Giuseppe; Benedetti, Fabio; Heinzelmann, Marion; Pastore, Domenico; Jurado, Manuel; Terruzzi, Elisabetta; Narni, Franco; Voelp, Andreas; Ayuk, Francis; Ruutu, Tapani; Kroeger, Nicolaus
Other contributor: University of Helsinki, Department of Medicine


Date: 2019-02
Language: eng
Number of pages: 11
Belongs to series: The lancet. Haematology
ISSN: 2352-3026
DOI: https://doi.org/10.1016/S2352-3026(18)30214-X
URI: http://hdl.handle.net/10138/311714
Abstract: Background We previously showed that human anti-T-lymphocyte globulin (ATLG) plus ciclosporin and methotrexate given to patients with acute leukaemia in remission, having allogeneic haemopoietic stem-cell transplantation with peripheral blood stem cells from an HLA-identical sibling donor after myeloablative conditioning, significantly reduced 2-year chronic graft-versus-host disease (cGVHD) incidence and severity, without increasing disease relapse and infections, and improves cGVHD-free and relapse-free survival (cGRFS). The aim of an extended follow-up study was the assessment of long-term outcomes, which are, in this context, scarcely reported in the literature. We report unpublished data on quality of life (QoL) from the original study and the results of a follow-up extension. Methods In the original open-label study, patients with acute myeloid and lymphoblastic leukaemia in first or subsequent remission, having sibling HLA-identical allogeneic peripheral blood stem-cell transplantation, were randomly assigned (1:1) to receive ATLG plus standard GVHD prophylaxis with ciclosporin and short-term methotrexate (ATLG group) or standard GVHD prophylaxis without ATLG (non-ATLG group). Conditioning regimens were cyclophosphamide 120 mg/kg with either total body irradiation (12 Gy) or busulfan (12 . 8 mg/kg intravenously or 16 mg/kg orally), with or without etoposide (30-60 mg/kg). Randomisation was stratified according to centre and disease risk. The primary endpoint was cumulative incidence of cGVHD at 2 years. The primary and secondary endpoints, excluding QoL, have been published. QoL, assessed using European Organisation for Research and Treatment of Cancer QLQ-C30 and QLQ-HDC29 questionnaires, was an unpublished secondary endpoint, which we now report here. A follow-up extension was then done, with the primary endpoint cumulative incidence of cGVHD. Enrolment has been completed for both studies. Findings In the original study, from Dec 14, 2006, to Feb 2, 2012, 161 patients were enrolled and 155 were randomly assigned to either the ATLG group (n=83) or to the non-ATLG group (n=72). In the follow-up study, which started on Feb 7, 2017, and was completed on June 30, 2017, 61 patients were included in the ATLG group and 53 were included in the non-ATLG group. Global health status showed a more favourable time course in the ATLG group compared with the non-ATLG group (p=0 . 02; treatment by visit interaction). ATLG was descriptively superior to non-ATLG at 24 months for physical function (points estimate -14.8 [95% CI -26.4 to-3.1]; p= 0.014) and social function (-19.1 [-38.0 to -0.2]; p=0.047), gastrointestinal side-effects (8 . 8 [2.5-15.1]; p=0 . 008) and effect on family (13.5 [1.2-25.8]; p=0.032). Extended follow-up (median 5 . 9 years [IQR 1.7-7.9]) confirmed a lower 5-year cGVHD incidence (30.0% [95% CI 21.4-41.9] vs 69.1% [59.1-80.1]; analysis for entire follow-up, p Interpretation The addition of ATLG to standard GVHD prophylaxis improves the probability of surviving without disease relapse and cGVHD after myeloablative peripheral blood stem-cell transplantation from an HLA-identical sibling donor for patients with acute leukaemia in remission. Further additional benefits are better QoL and shorter immunosuppressive treatment compared with standard GVHD prophylaxis without ATLG. Therefore, in this setting, ATLG plus standard GVHD prophylaxis should be preferred over the standard GVHD prophylaxis alone. Copyright (C) 2019 Elsevier Ltd. All rights reserved.
Subject: VERSUS-HOST-DISEASE
ANTI-THYMOCYTE GLOBULIN
T-LYMPHOCYTE GLOBULIN
MATCHED UNRELATED DONORS
RELAPSE-FREE SURVIVAL
OPEN-LABEL
HEMATOLOGICAL MALIGNANCIES
END-POINT
MULTICENTER
MARROW
3121 General medicine, internal medicine and other clinical medicine
Rights:


Files in this item

Total number of downloads: Loading...

Files Size Format View
Acute_GVHD_prophylaxis_plus_ATLG.pdf 718.7Kb PDF View/Open

This item appears in the following Collection(s)

Show full item record